Transcatheter Aortic Valve Implantation for Patients with Severe Symptomatic Aortic Stenosis


( Last Updated : July 21, 2021)
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC1367-000

Details


Question

  1. What is the cost-effectiveness of transcatheter aortic valve implantation or replacement in low-risk, intermediate-risk, and high-risk patients with severe symptomatic aortic stenosis undergoing this procedure?


Key Message

The cost-effectiveness of transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement was examined in patients with severe symptomatic aortic stenosis at high, intermediate, and low surgical risk, and the findings were mixed. When compared to surgical aortic valve replacement, some studies suggest that TAVI is cost-effective (less costly and/or more effective) and some studies suggest that TAVI is not cost-effective.

Factors such as the type of TAVI system used, the cost of treatment-associated expenses (such as post-operative follow-up costs and hospitalization costs), and the characteristics of patients selected for treatment likely impact the cost-effectiveness of TAVI for patients with severe symptomatic aortic stenosis.